Log in to save to my catalogue

Clinical trial links oncolytic immunoactivation to survival in glioblastoma

Clinical trial links oncolytic immunoactivation to survival in glioblastoma

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10620094

Publication information

Publisher

London: Nature Publishing Group UK

More information

Scope and Contents

Contents

Immunotherapy failures can result from the highly suppressive tumour microenvironment that characterizes aggressive forms of cancer such as recurrent glioblastoma (rGBM)
1
,
2
. Here we report the results of a first-in-human phase I trial in 41 patients with rGBM who were injected with CAN-3110—an oncolytic herpes virus (oHSV)
3
....

Alternative Titles

Full title

Clinical trial links oncolytic immunoactivation to survival in glioblastoma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10620094

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10620094

Other Identifiers

ISSN

0028-0836,1476-4687

E-ISSN

1476-4687

DOI

10.1038/s41586-023-06623-2

How to access this item